StocksMedium•12 November 2026•
1 min read
MacroGenics Reports Wider-Than-Expected Q3 Loss
Key Facts
1MacroGenics reported a quarterly loss of $0.34 per share, wider than the Zacks Consensus Estimate of a $0.1 loss.
2The current quarter's results compare to earnings of $0.27 per share reported a year ago.
MacroGenics reported a quarterly loss of $0.34 per share for the third quarter of 2026. Zacks reported that this figure was wider than the consensus estimate of a $0.1 loss per share, marking a significant miss for the biotechnology firm.
The current quarter's results compare to earnings of $0.27 per share reported in the same period last year according to Zacks. MGNX closed at $2.32 on November 11, 2026, with the stock trading between a low of $2.32 and a high of $2.42 during that session.